Study to Evaluate the Safety and Efficacy of Levetiracetam in Patients Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic Seizures
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00160550|
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : November 26, 2013
|Condition or disease||Intervention/treatment||Phase|
|Generalized Convulsive Epilepsy||Drug: Levetiracetam||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||154 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With 3000 mg/Day (Pediatric Target Dose of 60 mg/kg/Day) Oral Levetiracetam (LEV) (166, 250, and 500mg Tablets), in Adult and Pediatric Subjects (4-65 Years) Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic (PGTC) Seizures.|
|Study Start Date :||September 2001|
|Primary Completion Date :||June 2005|
|Study Completion Date :||June 2005|
- The percentage reduction from the combined Baseline Period in the PGTC seizure frequency per week over the Treatment Period (up-titration + evaluation).
- Reduction during the Treatment Period in PGTC seizure frequency
- Percentage reduction during the Treatment Period in seizure days
- Responder rates in PGTC seizure frequency, and in seizure days of all types.
- The safety parameters are the following: Laboratory tests; Adverse events; Electrocardiogram; Physical and neurological examinations
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00160550
|Study Director:||UCB Clinical Trial Call Center||UCB Pharma|